MGRX MANGOCEUTICALS, INC.
Services-Misc Health & Allied Services, NEC · Nasdaq · SEC CIK 1938046 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-35.6%
TTM net income YoY44.3%
TTM EPS YoY80.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin52.9%
Operating margin-2,608.1%
Net margin-3,673.7%
FCF margin—
EBITDA margin-2,607.7%
Returns
ROE-82.3%
ROA-69.8%
ROIC (approx.)-48.2%
Asset turnover0.02x
Leverage & solvency
Liabilities / assets9.4%
Debt / equity0.00x
Current ratio1.28x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.34x
Accruals ratio-45.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $456,021 | $615,873 | $731,493 | $8,939 |
| Cost of revenue | $54,422 | $93,296 | $154,900 | $4,089 |
| Gross profit | $250,386 | $379,964 | $431,501 | $4,850 |
| SG&A expense | $3.76M | $3.00M | $3.32M | $1.64M |
| Operating income | -$18.03M | -$7.97M | -$9.22M | -$1.99M |
| Interest expense | $103,513 | $13,700 | -$6,473 | $6,473 |
| Pretax income | -$20.64M | -$8.71M | -$9.21M | -$2.00M |
| Net income | -$20.64M | -$8.71M | -$9.21M | -$2.00M |
| EBITDA | -$18.03M | -$7.96M | -$9.19M | -$1.99M |
| EPS (basic) | -2.17 | -4.80 | -8.58 | -0.19 |
| EPS (diluted) | -2.17 | -4.80 | -8.58 | -0.19 |
| Weighted avg. shares (diluted) | 10.07M | 1.98M | 1.07M | 10.80M |
| Balance sheet | ||||
| Cash & equivalents | $1.49M | $58,653 | $739,006 | $682,860 |
| Inventory | — | — | $18,501 | — |
| Current assets | $1.55M | $75,595 | $835,402 | $694,605 |
| PP&E, net | $1,794 | $2,806 | $96,129 | $117,499 |
| Intangibles | $14.23M | $15.23M | — | — |
| Total assets | $16.09M | $15.37M | $1.05M | $1.00M |
| Current liabilities | $890,568 | $1.43M | $211,078 | $260,577 |
| Total liabilities | $890,568 | $1.43M | $276,039 | $389,257 |
| Shareholders' equity | $15.20M | $13.95M | $774,754 | $614,030 |
| Shares outstanding | 15.89M | 3.25M | 1.43M | 13.37M |
| Cash flow statement | ||||
| Operating cash flow | -$5.85M | -$4.86M | -$7.00M | -$1.35M |
| Capital expenditure | — | — | $3,519 | $43,102 |
| Free cash flow | — | — | -$7.00M | -$1.39M |
| Investing cash flow | — | $65,000 | -$3,519 | -$43,102 |
| Financing cash flow | $7.27M | $4.13M | $7.06M | $2.05M |
| Depreciation & amortization | $1,012 | $9,936 | $24,889 | $3,863 |
| Stock-based compensation | $1.17M | $248,682 | $624,463 | $234,088 |
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.